Introduction {#H1-1-ZOI200566}
============

Palliative care, which focuses on improving quality of life (QoL) through a multidisciplinary and holistic care approach, may offer an additional layer of support for those affected by chronic life-limiting illnesses. Palliative care has shown benefits in symptom intensity and QoL in patients with advanced cancer, and possible survival improvement.^[@zoi200566r1],[@zoi200566r2],[@zoi200566r3],[@zoi200566r4]^ Despite experiencing problems and care challenges similar to patients with advanced cancer, patients with chronic non-cancer conditions including long-term neurological conditions (LTNCs) are less likely to receive palliative care.^[@zoi200566r5],[@zoi200566r6]^

Neurological disorders are a major health burden, accounting globally for 10% of disability-adjusted life-years and 17% of deaths.^[@zoi200566r7]^ The LTNCs are a range of progressive neurodegenerative and other neurological disorders that affect an individual and their family for the rest of their lives. These conditions lead to substantial deterioration in QoL, require lifelong support from health and social care services, and often are an immense strain physically and emotionally on informal caregivers and family members.^[@zoi200566r6],[@zoi200566r8],[@zoi200566r9]^ Health care costs increase in advanced disease and are higher in those most severely affected.^[@zoi200566r10]^

There is a lack of robust evidence to support service and policy developments that improve palliative care provision for people with LTNCs.^[@zoi200566r11],[@zoi200566r12]^ To date, there are 3 published small-scale pilot or phase 2 randomized clinical trials of palliative care interventions in neurological conditions.^[@zoi200566r13],[@zoi200566r14],[@zoi200566r15]^ Findings of these trials reported slight improvements in symptom burden without harmful effects; however, they reported inconsistent effects on other outcomes (eg, QoL, caregiver burden). They also differed in key trial components, such as study population, intervention, outcome measures, and economic perspective.

Building on the phase 2 trial in multiple sclerosis (MS)^[@zoi200566r13]^ and a longitudinal observational study in advanced atypical parkinsonism,^[@zoi200566r16]^ we undertook this phase 3 trial to evaluate the clinical effectiveness and cost-effectiveness of short-term integrated palliative care (SIPC) among people severely affected by LTNCs, for improving symptoms and other patient and caregiver outcomes. Our primary null hypothesis was that there was no difference between study arms in their clinical effectiveness.

Methods {#H1-2-ZOI200566}
=======

Study Design and Setting {#H2-1-ZOI200566}
------------------------

Pragmatic phase 3, multicenter, randomized clinical trial of the clinical effectiveness and cost-effectiveness of SIPC for people with advanced LTNCs. Patients were recruited from 7 national hospitals with both neurology services and multiprofessional palliative care teams in the UK. Within study sites, a broad range of services were offered, including voluntary and National Health Services hospices, hospital and community based multidisciplinary palliative care, as well as tertiary and secondary neurological services.^[@zoi200566r5]^ This trial and its protocol were approved by the London South East Research Ethics Committee. Patients and caregivers gave written informed consent. The trial protocol and intervention manual are available in [Supplement 1](#note-ZOI200566-1-s){ref-type="supplementary-material"}. This study followed the Consolidated Standards of Reporting Trials ([CONSORT](https://www.equator-network.org/reporting-guidelines/consort/)) reporting guideline for randomized clinical trials..

Participants {#H2-2-ZOI200566}
------------

Patients severely affected by LTNCs and their caregivers were identified by a neurologist or a clinical nurse specialist and referred to the trial. The recruitment period was from April 1, 2015, to November 30, 2017, with a last follow-up date of May 31, 2018. Data were analyzed from November 2018 to March 2019.

For patients, inclusion criteria included (1) adults (aged ≥18 years) severely affected by advanced or progressive stages of 1 of the following: MS (usually Expanded Disability Status Scale score ≥7.5 \[range, 0 indicates no disability in any functional system and 10 indicates death due to MS), all stages of motor neuron disease (MND), idiopathic Parkinson disease (IPD, Hoehn and Yahr stages 4-5), progressive supranuclear palsy (adapted Hoehn and Yahr stages 3-5) and multiple system atrophy (adapted Hoehn and Yahr stages 3-5); (2) an unresolved symptom which had not responded to standard care; and (3) at least 1 of the following: an unresolved other symptom; cognitive problems or complex psychological issues; communication or information problems or complex social need. Exclusion criteria included already receiving specialist palliative care, lacking mental capacity, and having no one available to advise on their behalf to provide proxy data.

For informal caregivers, inclusion criteria were adults identified by the patient as a person close to them who was able and willing to complete questionnaires. If the caregiver was unavailable or declined participation, only the patient was enrolled.

Randomization and Masking {#H2-3-ZOI200566}
-------------------------

Randomization was undertaken independently by the UK Clinical Research Collaboration--registered King's Clinical Trials Unit. Following patient consent and baseline data collection, randomization was performed in a 1:1 ratio, at the patient level with minimization for center, primary diagnosis (MS vs IPD vs progressive supranuclear palsy, multiple system atrophy and MND), and cognitive impairment (capacity vs impaired or lacking capacity). The data collectors (W.G. and I.J.H.) and the statistical and health economic analysis team (W.G., R.W., and D.Y.) were blinded to the group allocation until after the main analyses were completed and reported to the study steering committee.

SIPC Intervention {#H2-4-ZOI200566}
-----------------

SIPC focused on a comprehensive assessment, personalized care planning, case management and care coordination, and advising existing care providers. It was developed and evaluated using the Medical Research Council framework for evaluating complex interventions. SIPC was delivered by existing multiprofessional palliative care teams, linked with local neurology services. All staff involved in the delivery of the intervention were provided with a standard manual ([Supplement 1](#note-ZOI200566-1-s){ref-type="supplementary-material"}) and face-to-face training in advance of the trial commencing. The intervention manual described the core elements to be covered when assessing patients as part of SIPC as well as the minimum standards for capturing and reporting delivery of SIPC.

SIPC usually lasted from 6 to 8 weeks from referral. Following referral, a key worker contacted the patient within 2 working days to arrange a visit within the next 5 working days. At this initial visit, a comprehensive palliative care assessment was undertaken considering both patient and caregiver and family needs. A problem list was generated, and a proposed care plan was developed to which the patient and their family agreed. The second contact (face-to-face or telephone) normally occurred within 2 weeks of the first visit to review progress with the care plan. The final contact involved a review of outcomes from actions already taken before discharge to local services as appropriate. The control arm continued to receive usual care services until after 12-weeks at which point they were referred to SIPC. A summary of the intervention is presented in [Table 1](#zoi200566t1){ref-type="table"}.

###### Details of SIPC and Standard Care

  Timeline                                                                                      SIPC                                                                                                  Standard care
  --------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------
  Consent and baseline interview                                                                Baseline research interview and consent before randomization                                          Baseline research interview and consent before randomization
  Randomization                                                                                                                                                                                       
  2 working days from receiving referral                                                        Palliative care assessment within 2 working days                                                      NA
  Weeks                                                                                                                                                                                               
  1-6                                                                                           Palliative care, including assessment, treatment, referral, review                                    NA
  6                                                                                             Research interview 6 weeks post randomization.                                                        Research interview 6 weeks postrandomization
  6-8                                                                                           Palliative care continues lasting 6-8 weeks, with referral on for those needing long-term care        NA
  12-weeks (primary end point)                                                                  Research interview 12 weeks postrandomization                                                         Research interview 12 weeks postrandomization
  2 working days from receiving referral (following completion of 12-week research interview)   NA                                                                                                    Standard care group now offered palliative care within 2 working days of receiving referral
  Weeks                                                                                                                                                                                               
  12-18                                                                                         Discharge from palliative care team (if referred to community team, this continues from this point)   Palliative care, including assessment, treatment, referral, review
  18                                                                                            Research interview 18 weeks postrandomization                                                         Research interview 18 weeks post randomization
  18-20                                                                                         NA                                                                                                    Palliative care continues lasting 6 to 8 weeks, with referral on for those needing long-term care
  24                                                                                            Final research interview 24 weeks postrandomization                                                   Final research interview 24 weeks postrandomization
  24-26                                                                                         NA                                                                                                    Discharge from palliative care team (if referred to community team, this continues from this point)

Abbreviations: NA, not applicable; SIPC, short-term integrated palliative care.

Data Collection {#H2-5-ZOI200566}
---------------

Data were collected at baseline and then 6-weekly until 24-weeks post randomization. Trained research nurses/researchers assisted as required in self-completion of patient and caregiver questionnaires according to the standardized schedule during their face-to-face visits. Ethnicity was self-defined by participants. We collected this data as it is a known confounder for accessing health care services. Caregivers usually self-completed their questionnaires during the patient interview. For adults lacking capacity, baseline and outcome measures were obtained from the informal caregiver. The qualitative study comprised interviews with patients and caregivers after SIPC was completed.

Outcomes {#H2-6-ZOI200566}
--------

The outcome measures used in this study are presented in eTable 1 in [Supplement 2](#note-ZOI200566-1-s){ref-type="supplementary-material"}. The primary outcome was the change score between baseline and at 12-weeks in 8 symptoms (pain, shortness of breath, nausea, vomiting, constipation, spasms, difficulty sleeping, and mouth problems) as measured by the Integrated Palliative care Outcome Scale for Neurological conditions (IPOS Neuro-S8; each item was rated on a 5-point Likert scale in which 0 indicates no problem and 4 indicates an overwhelming problem; total score ranges from 0-32).^[@zoi200566r17]^ Secondary outcomes for patients were changes in other palliative care symptoms, palliative care needs, psychological stress, health-related QoL and satisfaction. For caregivers, outcomes included caregiver burden and positivity as well as satisfaction. Patient-reported health service use was collected using the Client Services Receipt Inventory.^[@zoi200566r18]^ For patients unable to convey outcomes, we collected caregiver's assessment of patient's problems and service use. As safety measures, we monitored serious adverse events, adverse events, and survival.

Data Analysis {#H2-7-ZOI200566}
-------------

Given 80% power and 2-tailed significance of 5%, it was estimated that we needed to recruit 356 patients (178 per arm) to detect a small to medium effect size of 0.3 in the primary outcome, equivalent to a score change of 1.0 in the IPOS Neuro-S8 from baseline to 12 weeks postrandomization. The minimal clinically important difference in IPOS Neuro-S8 as estimated by a third of the standard deviation was 1.1.^[@zoi200566r17]^ This estimation assumed a correlation coefficient of 0.4 between baseline and 12-week scores and 17% attrition. The parameters for sample size estimation were from previous studies.^[@zoi200566r13],[@zoi200566r16]^

This paper reports baseline and at 12-week data only. Missing data were summarized according to the Methods of Researching End of Life Care classification.^[@zoi200566r19]^ The mechanism of missing was assumed missing at random. Multiple imputation using chained equations was used to impute missing data. Twenty copies of imputed values were generated for each variable with missing data.

For baseline and outcome data, observations with complete data at both times were reported. Continuous variables were summarized using mean (standard deviation) and median (range) as appropriate. Categorical variables were reported as frequency counts and percentage.

Intention-to-treat analysis was carried out using generalized linear mixed model with center modeled as a random effect, adjusting for baseline score. The mean change scores from baseline to 12 weeks, effect sizes and their 95% CIs were reported. Effect sizes were calculated from model-based point estimates (95% CIs) of effect for individual outcomes divided by respective SDs, derived from standard errors using the method described previously.^[@zoi200566r20]^ Survival was compared using the 2-sample *t* test and adverse events were compared using the χ^2^ test.

Six sensitivity analyses were conducted to assess the robustness of the findings from the main analysis: (1) the comparison between arms also accounted for the difference in ethnicity as there were more White individuals in SIPC than in the control arm (94.3% vs 86.2%; *P* = .009); (2) the 2 participants who were deemed ineligible postrandomization were excluded, thus the sample size for this analysis was 348; (3) we assessed differences in change scores between trial arms in complete patient data; (4) we assessed differences in change scores between trial arms in caregiver data; (5) we used complete patient data, if available at both baseline and week 12, and imputed proxy caregiver data if not; and (6) we evaluated the primary and secondary outcomes for patients with MS only to compare the effects of SIPC in this trial with that of the Phase 2 MS trial.^[@zoi200566r13]^

The interaction effect between treatment and trial center on outcomes was explored by including a product term in the generalized linear mixed models. The *P* values were examined.

To determine the cost of SIPC, a base case incremental analysis from an NHS perspective was conducted. We valued health and social care use from the Client Services Receipt Inventory for the past 3 months at baseline and at 12 weeks by multiplying use by specific unit cost data from standard sources (eTable 9 in [Supplement 2](#note-ZOI200566-1-s){ref-type="supplementary-material"}).

All significance tests were 2-sided at the level of .05 (primary and cost outcomes) or 0.0045 (secondary outcomes, Bonferroni correction to control for multiple testing 0.05 divided by 11 \[total number of tests on the secondary outcomes\]). Statistical analyses were performed in parallel using SAS, version 9.4 (SAS Institute Inc) and Stata, version 14 (StataCorp Inc).

Qualitative interviews were digitally recorded, transcribed verbatim, and anonymized prior to analysis. The data were analyzed thematically using the Coffey and Atkinson iterative approach.^[@zoi200566r21]^

Results {#H1-3-ZOI200566}
=======

A total of 535 participants were assessed for eligibility. Among the 492 participants who met eligibility criteria, we recruited and randomized 350 patients and 229 caregivers across 7 centers, with 176 patients randomized to SIPC and 174 patients randomized to standard care ([Figure](#zoi200566f1){ref-type="fig"}). Patients' mean (SD) age was 67 (12), and 179 (51%) were men ([Table 2](#zoi200566t2){ref-type="table"}). Multiple sclerosis (N = 148) and IPD (N = 140) were the 2 most common diagnosed conditions. Patients had been living with their conditions for a median of 12 years (range, 0-56 years), 39 patients (11%) had cognitive impairment and approximately 60% of patients required either considerable assistance or total care for daily living.

![Consort Diagram Showing the Flow of Patients in OPTCARE Neuro Trial](jamanetwopen-3-e2015061-g001){#zoi200566f1}

###### Demographic and Clinical Characteristics of Patients and Caregivers

  Variable                                                                          No. (%)                                   
  --------------------------------------------------------------------------------- ------------- ------------- ------------- -------------
  No.                                                                               176           174           121           108
  Age, mean (SD), y                                                                 67.3 (10.9)   66.4 (12.6)   63.3 (13.3)   65.3 (13.4)
  Sex                                                                                                                         
  Male                                                                              86 (48.9)     93 (53.5)     41 (33.9)     40 (37.0)
  Female                                                                            90 (51.1)     81 (46.6)     80 (66.1)     68 (63.0)
  Marital status                                                                                                              
  Single                                                                            16 (9.1)      19 (10.9)     7 (5.8)       7 (6.5)
  Widowed                                                                           19 (10.8)     19 (10.9)     4 (3.3)       6 (5.6)
  Married/civil partner                                                             114 (64.8)    117 (67.2)    109 (90.1)    91 (84.3)
  Divorced/separated                                                                26 (14.8)     18 (10.3)     1 (0.8)       4 (3.7)
  Not done/unknown                                                                  1 (0.6)       1 (0.6)       NA            NA
  Living status                                                                                                               
  Alone                                                                             35 (19.9)     30 (17.2)     4 (3.3)       5 (4.6)
  Spouse/partner and/or children                                                    125 (71.0)    119 (68.4)    109 (90.1)    91 (84.3)
  Friend(s)/with others                                                             16 (9.1)      25 (14.4)     8 (6.6)       12 (11.1)
  Education                                                                                                                   
  No formal education                                                               67 (38.1)     72 (41.4)     51 (42.2)     45 (41.7)
  Upper secondary to postsecondary vocational qualification                         53 (30.1)     63 (36.2)     37 (30.6)     29 (26.9)
  Tertiary education                                                                55 (31.3)     36 (20.7)     30 (24.8)     32 (29.6)
  Not done/missing                                                                  1 (0.6)       3 (1.7)       3 (2.5)       2 (1.9)
  Race/ethnicity                                                                                                              
  White                                                                             166 (94.3)    150 (86.2)    113 (93.4)    98 (90.7)
  Other ethnic group^a^                                                             9 (5.1)       23 (13.2)     8 (6.6)       10 (9.3)
  Employment                                                                                                                  
  No                                                                                173 (98.3)    167 (96.0)    86 (71.1)     76 (70.4)
  Yes                                                                               3 (1.7)       7 (4.0)       35 (28.9)     32 (29.6)
  Relationship to patient                                                                                                     
  Spouse/partner                                                                    NA            NA            97 (80.2)     80 (74.1)
  Son/daughter                                                                      NA            NA            17 (14.1)     12 (11.1)
  Other                                                                             NA            NA            0             4 (3.7)
  Having illness                                                                                                              
  Yes                                                                               NA            NA            70 (57.9)     70 (64.8)
  No                                                                                NA            NA            41 (33.9)     36 (33.3)
  Feelings on present income                                                                                                  
  Living comfortably                                                                58 (33.0)     60 (34.5)     NA            NA
  Coping                                                                            85 (48.3)     77 (44.3)     NA            NA
  Difficult                                                                         12 (6.8)      12 (6.9)      NA            NA
  Very difficult                                                                    7 (4.0)       7 (4.0)       NA            NA
  Not done/unknown                                                                  14 (8.0)      18 (10.3)     NA            NA
  Diagnosis                                                                                                                   
  Multiple sclerosis                                                                74 (42.1)     74 (42.5)     NA            NA
  Idiopathic Parkinson disease                                                      71 (40.3)     69 (39.7)     NA            NA
  Multiple system atrophy                                                           7 (4.0)       5 (2.9)       NA            NA
  Progressive supranuclear palsy[^b^](#zoi200566t2n2){ref-type="table-fn"}          13 (7.4)      14 (8.1)      NA            NA
  Motor neuron disease                                                              11 (6.3)      12 (6.9)      NA            NA
  Time since diagnosis, median (range), y                                           12.3 (0-56)   12.4 (0-46)   NA            NA
  Comorbidities                                                                                                               
  Yes                                                                               134 (76.1)    117 (67.2)    NA            NA
  No                                                                                42 (23.9)     57 (32.8)     NA            NA
  Consent                                                                                                                     
  Patient consent                                                                   157 (89.2)    154 (88.5)    NA            NA
  Personal consultee assent                                                         19 (10.8)     20 (11.5)     NA            NA
  Functional status as measured by AKPS[^c^](#zoi200566t2n3){ref-type="table-fn"}                                             
  Totally bedfast                                                                   3 (1.7)       4 (2.3)       NA            NA
  Almost completely bedfast                                                         5 (2.8)       5 (2.9)       NA            NA
  In bed \>50% of the time                                                          10 (5.7)      11 (6.3)      NA            NA
  Requires considerable assistance                                                  77 (43.8)     93 (53.5)     NA            NA
  Requires occasional assistance                                                    54 (30.7)     44 (25.3)     NA            NA
  Cares for self                                                                    19 (10.8)     14 (8.1)      NA            NA
  Normal activity with effort                                                       7 (4.0)       2 (1.2)       NA            NA
  Not available/applicable/not done                                                 1 (0.6)       1 (0.6)       NA            NA

Abbreviations: NA, not applicable; SIPC, short-term integrated palliative care.

Other includes mixed/multiple ethnic groups, Asian/Asian British, Black/African/Caribbean/Black British, other ethnic group, don\'t know, prefer not to say, not available or not applicable, not done, or unknown.

Includes N = 2 patients with Corticobasal Degeneration.

The Australia-modified Karnofsky Performance Scale (100 -- Normal to 0 -- Dead).

Primary and Secondary Clinical Outcomes {#H2-8-ZOI200566}
---------------------------------------

There were no statistically significant differences between trial arms for the primary outcome (effect size, −0.16; 95% CI, −0.37 to 0.05) or any of the secondary outcomes (effect size range, −0.20 to 0.12; *P* value range, 0.06 - 0.90). There was a small but statistically significant reduction in symptom burden at 12 weeks in the SIPC group (IPOS Neuro-S8, −0.78; 95%CI, −1.29 to −0.26) ([Table 3](#zoi200566t3){ref-type="table"}). Most other patient outcomes were consistent: score changes in the control arm had either a smaller but statistically insignificant improvement or a greater decrease than the corresponding figures in the SIPC group. Results of the sensitivity analyses confirmed the robustness of the findings (eTables 2-7 in [Supplement 2](#note-ZOI200566-1-s){ref-type="supplementary-material"}). None of the interaction between treatment and site on primary outcome or secondary outcomes was statistically significant. Neither adverse events nor survival was statistically different between the 2 groups

###### Results of Primary and Secondary[^**a**^](#zoi200566t3n1){ref-type="table-fn"} Outcomes Using Multiply Imputed Data From All Recruited Patients

  Measure                         SEM (95% CI)             *P* value[^b^](#zoi200566t3n2){ref-type="table-fn"}                           
  ------------------------------- ------------------------ ----------------------------------------------------- ----------------------- -----
  Primary outcome                                                                                                                        
  IPOS Neuro-S8                                                                                                                          
  Baseline                        6.89 (6.24 to 7.54)      6.96 (6.34 to 7.58)                                   NA                      NA
  12-wk                           6.11 (5.46 to 6.77)      6.68 (6.02 to 7.34)                                   NA                      NA
  Change score                    −0.78 (−1.29 to −0.26)   −0.28 (−0.82 to 0.26)                                 −0.16 (−0.37 to 0.05)   .14
  Secondary patient outcome                                                                                                              
  IPOS Neuro-S24                                                                                                                         
  Baseline                        26.69 (24.23 to 29.15)   27.16 (24.57 to 29.75)                                NA                      NA
  12-wk                           24.74 (22.10 to 27.37)   26.27 (23.58 to 28.96)                                NA                      NA
  Change score                    −1.95 (−4.38 to 0.48)    −0.89 (−3.15 to 1.36)                                 −0.13 (−0.34 to 0.08)   .22
  IPOS Neuro 8                                                                                                                           
  Baseline                        11.43 (10.07 to 12.79)   11.58 (10.09 to 13.08)                                NA                      NA
  12-wk                           10.59 (9.09 to 12.09)    11.80 (10.34 to 13.26)                                NA                      NA
  Change score                    −0.84 (−2.09 to 0.40)    0.21 (−1.25 to 1.68)                                  −0.20 (−0.41 to 0.01)   .06
  IPOS Neuro                                                                                                                             
  Baseline                        47.36 (41.94 to 52.78)   46.72 (40.93 to 52.51)                                NA                      NA
  12-wk                           43.14 (35.28 to 51.00)   44.22 (37.55 to 50.89)                                NA                      NA
  Change score                    −4.22 (−10.87 to 2.43)   −2.50 (−8.37 to 3.37)                                 −0.07 (−0.28 to 0.15)   .53
  HADS anxiety                                                                                                                           
  Baseline                        7.78 (6.78 to 8.77)      7.51 (6.52 to 8.50)                                   NA                      NA
  12-wk                           7.43 (6.28 to 8.58)      7.59 (6.53 to 8.66)                                   NA                      NA
  Change score                    −0.35 (−1.12 to 0.43)    0.08 (−0.65 to 0.81)                                  −0.12 (−0.33 to 0.09)   .27
  HADS depression                                                                                                                        
  Baseline                        8.13 (7.29 to 8.97)      8.31 (7.47 to 9.16)                                   NA                      NA
  12-wk                           7.96 (7.03 to 8.88)      8.22 (7.35 to 9.09)                                   NA                      NA
  Change score                    −0.17 (−0.79 to 0.45)    −0.09 (−0.78 to 0.59)                                 −0.04 (−0.25 to 0.17)   .69
  EQ-5D VAS                                                                                                                              
  Baseline                        52.72 (47.91 to 57.53)   52.25 (47.01 to 57.49)                                NA                      NA
  12-wk                           53.69 (48.03 to 59.34)   50.75 (45.36 to 56.14)                                NA                      NA
  Change score                    0.97 (−5.01 to 6.94)     −1.50 (−8.05 to 5.05)                                 0.12 (−0.09 to 0.33)    .27
  SEMCD                                                                                                                                  
  Baseline                        5.39 (4.89 to 5.89)      5.13 (4.63 to 5.64)                                   NA                      NA
  12-wk                           5.28 (4.75 to 5.82)      4.94 (4.41 to 5.47)                                   NA                      NA
  Change score                    −0.10 (−0.60 to 0.40)    −0.19 (−0.70 to 0.31)                                 0.10 (−0.11 to 0.31)    .37
  FAMCARE P16 (patient version)                                                                                                          
  Baseline                        50.33 (46.66 to 54.00)   50.30 (47.08 to 53.53)                                NA                      NA
  12-wk                           48.08 (43.75 to 52.41)   47.41 (43.52 to 51.31)                                NA                      NA
  Change score                    −2.26 (−6.05 to 1.53)    −2.89 (−6.23 to 0.45)                                 0.04 (−0.17 to 0.25)    .70
  Secondary caregiver outcome                                                                                                            
  ZBI 12                                                                                                                                 
  Baseline                        18.25 (15.59 to 20.90)   18.68 (16.28 to 21.08)                                NA                      NA
  12-wk                           18.60 (15.93 to 21.27)   18.92 (16.28 to 21.55)                                NA                      NA
  Change score                    0.35 (−0.98 to 1.68)     0.24 (−1.15 to 1.64)                                  0.01 (−0.20 to 0.22)    .90
  ZBI Positivity                                                                                                                         
  Baseline                        18.97 (17.36 to 20.59)   18.72 (17.05 to 20.38)                                NA                      NA
  12-wk                           18.87 (17.08 to 20.67)   18.12 (16.15 to 20.10)                                NA                      NA
  Change score                    −0.10 (−1.43 to 1.23)    −0.59 (−1.98 to 0.79)                                 0.09 (−0.12 to 0.30)    .40
  FAMCARE 2 (carer version)                                                                                                              
  Baseline                        53.81 (49.64 to 57.97)   53.98 (49.93 to 58.02)                                NA                      NA
  12-wk                           53.99 (48.92 to 59.07)   53.23 (48.38 to 58.07)                                NA                      NA
  Change score                    0.19 (−4.86 to 5.23)     −0.75 (−4.64 to 3.14)                                 0.05 (−0.17 to 0.26)    .67

Abbreviations: EQ-5D VAS, EuroQoL 5-dimension visual analogue scale; HADS, Hospital Anxiety and Depression Scale; IPOS Neuro-S8, Integrated Palliative care Outcome Scale for Neurological conditions (contains 8 key symptoms); IPOS Neuro-S24, Integrated Palliative care Outcome Scale for Neurological conditions (contains 24 physical symptoms); NA, not applicable; SEM, standard error of the mean; SEMCD, Self-efficacy for Managing Chronic Disease; and ZBI, Zarit Burden Interview.

95% confidence interval for primary outcome; 99.55% confidence intervals for secondary outcomes, Bonferroni correction to control for multiple testing (adjusted α = 0.0045,0.05/11).

*P* value for 2 group comparisons using generalized linear mixed model, adjusting for baseline score with center modeled as a random effect.

Adverse Events and Survival Outcome {#H2-9-ZOI200566}
-----------------------------------

There were 5 deaths, 13 hospitalizations, and 2 emergency department visits up to 12 weeks in the SIPC group. The corresponding figures for the control arm were 3 deaths, 12 hospitalizations, and 5 emergency department visits up to 12 weeks. Survival between the 2 groups was comparable (11.6 vs 11.8 weeks). Neither adverse events (*P* = .61) nor survival (*P* = .28) was statistically different between the 2 groups.

Health Economic Outcomes {#H2-10-ZOI200566}
------------------------

There was a decrease in mean (95% CI) health and social care costs from baseline to 12 weeks −\$1367 (95% CI, −\$2450 to −\$282) in the SIPC group and −653 (95% CI, −\$1839 to −\$532) in the control group (eTable 10 in [Supplement 2](#note-ZOI200566-1-s){ref-type="supplementary-material"}). No significant differences were found between groups for the change scores of EuroQoL 5-dimension index score (0.04; 95% CI, −0.02 to 0.09; *P* = .08).

Results of Qualitative Analysis {#H2-11-ZOI200566}
-------------------------------

Patients (N = 26) and caregivers (N = 16) participated in 26 qualitative interviews from 3 trial centers (London, Brighton, Ashford-Surrey). The characteristics of participants are shown in eTable 11-12 in [Supplement 2](#note-ZOI200566-1-s){ref-type="supplementary-material"}. Similar to the main sample, patients mostly had MS (69%) and had lived with their condition a median of 11 years. The themes of SIPC assessed by patients and caregivers included adapting to losses and building resilience, attending to function, deficits and maintaining stability, and enabling carers to care (eTable 13 in [Supplement 2](#note-ZOI200566-1-s){ref-type="supplementary-material"}).

Discussion {#H1-4-ZOI200566}
==========

In this randomized clinical trial of palliative care in people with LTNCs, none of the evaluated outcomes were significantly different between the 2 groups, nor were adverse events, survival, or withdrawals. However, we found a small and statistically significant reduction in both the primary outcome and care costs in the intervention group. Health economic analyses suggested that SIPC may deliver better outcomes at a lower cost than standard care.

The heterogeneity of the disorders studied may have been factors in the non-significant results of the trial. IPD, MND, and MS differ in pathophysiology, clinical profiles, natural history as well as endophenotypes. Many consider IPD itself to be a syndrome^[@zoi200566r23]^ and subtypes within MND and MS are also well recognized. Aspects related to non-motor symptoms of these disorders, particularly IPD, may also be substantially different from MS and MND, and may lead to the data being difficult to capture.^[@zoi200566r24],[@zoi200566r25]^ Variations across centers, for example how the eligibility criteria were applied to recruit patients (eTable 8 in [Supplement 2](#note-ZOI200566-1-s){ref-type="supplementary-material"}), the way the intervention was organized and delivered,^[@zoi200566r5]^ may also have played a role in the intervention effect. Although the sample size was inflated to account for the heterogeneity when planning the study and training had been provided to ensure the consistency of key trial elements, it appeared that the heterogeneity was largely underestimated. The observed effect of SIPC in this trial was overall much smaller than that of the phase 2 trial (−0.14 vs −0.80).^[@zoi200566r26]^

Outcome measures may be another factor in the interpretation of the intervention effects. The primary outcome was selected based on the 5 symptoms that were most responsive to the palliative care intervention in the phase 2 trial and additional symptoms from a longitudinal observational study of advanced Parkinson disease and atypical parkinsonism.^[@zoi200566r13],[@zoi200566r16]^ Preliminary psychometric evaluations found that the measure exhibited good psychometric properties.^[@zoi200566r17],[@zoi200566r27]^ In this trial, several items of the IPOS Neuro-S8 as well as the IPOS Neuro-S24 showed floor effects at baseline. However, per the eligibility criteria, the patients recruited should have unresolved symptoms, which the referring clinicians deemed to require input from specialist palliative care, especially in non-motor symptoms. Not all symptoms may be adequately captured by our outcome measures; therefore, further refinement of the outcome measures may be necessary.

Limitations {#H2-12-ZOI200566}
-----------

This study has limitations. The sample was largely composed of patients with MS and IPD who tend to have a longer disease course. It is possible that the baseline symptom profiles and therefore the subsequent experience of SIPC are different for patients with LTNCs with a more rapid progression. Although every effort was made to standardize SIPC and our fidelity data showed that the intervention overall managed well (eTable 14 in [Supplement 2](#note-ZOI200566-1-s){ref-type="supplementary-material"}), there were differences across centers. The intraclass correlation coefficient of 0.12 for IPOS Neuro-S8 was high but was not accounted for in our sample size estimation. The intervention teams were a mix of hospice based and hospital based, which led to differences in the make-up of their multidisciplinary teams as well as the services they were able to offer. There may have been contamination whereby participants in the control arm received components of SIPC.

Conclusions {#H1-5-ZOI200566}
===========

In this randomized clinical trial of SIPC vs standard care, there were no differences in patient reported outcomes or adverse events. Refining referral criteria to better match patients to SIPC and intervention optimization may help to support wider implementation of this new care model in practice.

###### 

**Trial Protocol and Intervention Manual**

###### 

Click here for additional data file.

###### 

**eTable 1.** Outcome measures used in OPTCARE Neuro trial

**eTable 2.** Means and Change Scores of Primary (95% CIs) and Secondary Outcomes (99.55% CIs) at Baseline and 12-Weeks Post Randomisation by Trial Arm, Using Multiply Imputed Data From All Recruited Patients

**eTable 3.** Means and Change Scores of Primary (95% CIs) and Secondary Outcomes (99.55% CIs) at Baseline and 12-Weeks Post Randomisation, by Trial Arm, Using Multiply Imputed Patient Data Excluding Two Ineligible Patients

**eTable 4.** Means and Change Scores of Primary (95% CIs) and Secondary Outcomes (99·55% CI) at Baseline and 12-Weeks Post Randomisation, by Trial Arm, Using Complete Patient Data at Both Baseline and 12-Weeks

**eTable 5.** Means and Change Scores of Primary (95% CIs) and Secondary Outcomes (99·55% CI) at Baseline and 12-Weeks post Randomisation, by Trial Arm, Using Carers With Complete Data at Both Baseline and 12-Weeks

**eTable 6.** Means and Change Scores of Primary (95% CIs) and Secondary Outcomes (99·55% CI) at Baseline and 12-Weeks Post Randomisation, by Trial Arm, Using Patients With Complete Data at Both Baseline and 12-Weeks Plus Imputed Proxy Data if Available at Both Baseline and 12-Weeks

**eTable 7.** Means and Change Scores of Primary (95% CIs) and Secondary Outcomes (99·55% CI) at Baseline and 12-Weeks Post Randomisation by Trial Arm, Using Multiply Imputed Data From Patients With Multiple Sclerosis Only

**eTable 8.** Participant Characteristics by Study Site

**eTable 9.** Unit Costs of Health and Social Care Services in the Analysis

**eTable 10.** Average Care Costs per Person (95% Confidence Intervals) at Baseline and 12 Weeks Post Randomisation, and Changes in Health and Social Care Costs by Trial

**eTable 11.** Patient Demographics for Qualitative Interview Participants

**eTable 12.** Carer Demographics for Qualitative Interview Participants

**eTable 13.** Analytic Framework for the Qualitative Data on the Value and Impact of SIPC

**eTable 14.** Analysis of Fidelity Data

###### 

Click here for additional data file.

###### 

**Data Sharing Statement**

###### 

Click here for additional data file.
